# Aldeyra Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aldeyra-therapeutics

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.aldeyra.com
- Total disclosed funding: $4.8M
- Latest round: Series B (Dec 20, 2012)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2004 by CEO Todd C. Brady, Aldeyra Therapeutics, Inc., aka Aldeyra Therapeutics, develops pharmaceuticals that modulate immunological systems instead of directly inhibiting or activating single protein targets to minimize toxicity to treat immune-mediated diseases. In December 2012, Aldeyra Therapeutics, Inc. raised USD 4.79 million in Series B funding from Johnson & Johnson and Domain Associates.

The company's product line includes RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases such as dry eye disease and allergic conjunctivitis. In addition, the firm also offers products for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, other retinal diseases, autoimmune disease, and cancer.

## Funding rounds

- Series B, Dec 20, 2012, $4.8M — Domain Associates, Johnson & Johnson Innovation

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B